

Synergistic Effect of Pegylated Interferon and Ruxolitinib in the Treatment of Resistant Essential Thrombocytosis

Oskar Lepiarczyk and Aaron Niblock*

Consultant Haematologist, Antrim Area Hospital, United Kingdom

*Corresponding author: Aaron Niblock, Consultant Haematologist, Antrim Area Hospital, United Kingdom. E-mail: aaronniblock@doctors.net.uk

Received: May 25, 2022; Accepted: June 11, 2022; Published: June 28, 2022

Introduction

Essential thrombocytemia (ET) is a myeloproliferative neoplasm, which are a group that feature clonal proliferation of myeloid cells. Other entities in this group include Polycythaemia Vera and Myelofibrosis. There is recognised association between MPNs and somatic mutations of JAK2V617F, CALR or MPL genes [1]. Their driving influence on cell proliferation has been a milestone development in diagnostic process as well as potential new avenue for treatment. Specifically for ET, in more than 90% of cases a mutation of one of the above genes can be identified (JAK2: 60-65%; CALR: 20-25%; MPL: 7%) [1]. The risks of ET include thrombosis, transformation to myelofibrosis or acute myeloid leukaemia [3]. The cornerstone of treatment is to stratify the patients into thrombotic risk at diagnosis. High risk individuals are either >60yrs of age or had an ET related thrombotic or haemorrhagic event or platelets >1500 x 10⁹/l. Treatment of high risk individuals include aspirin, Hydroxycarbamide (or interferon in the young) as first line therapy to maintain the platelet count <400 x 10⁹/l [3,4]. Hydroxycarbamide is currently the backbone of treatment in ET and resistance/intolerance can occur in up to 20% of cases. The following case describes the difficulty in treating a young patient refractory to first line therapy and overcoming resistance to novel JAK inhibitors [5].

Case Description

This 55 year old gentleman of afro-Caribbean background and previous medical history of T2DM presented to our haematology department in early 2021 following admission with COVID pneumonitis. He was referred due to poorly controlled ET with a platelet count of 1200 x 10⁹/l. He was currently on 2g Hydroxycarbamide and 25mg Ruxolitinib. He was originally diagnosed over 10 years prior in another country. After retrieval of his original notes it was clear that the patient have refractory disease and was currently on a trial receiving Ruxolitinib. When he first was diagnosed with ET he received peg interferon that was titrated up to 135mcg. The patient struggled with gastrointestinal side effects and his platelets at best were 900 x 10⁹/l.

He was switched to Anagrelide and that was stopped due to palpitations and the finding of a prolonging QT. He was then switched to Hydroxycarbamide and this was titrated up to 2grams/day. His platelet count went up consistently greater than $1000 \times 10^9/l$. The case was proving difficult and therefore he was started on the JAK2v617F inhibitor Ruxolitinib 25mg twice a day. Shortly afterwards the patient travelled for work reasons and was admitted under our care. Given the history and lack of therapeutic options we repeated the bone marrow biopsy which was consistent with the known ET and had no excess reticulin. At first we re-trialled low dose (90mcg) of pegylated interferon alpha keeping both the Ruxolitinib, Hydroxycarbamide and aspirin going. After 48 hours the platelet count reduced to $823 \times 10^9/l$. At this stage the patient was initially reluctant to increase the peg interferon to a higher dose of 135mcg due to previous side effects. Interestingly at 135mcg the patient had no gastrointestinal upset and quickly the platelets fell to $422 \times 10^9/l$. The Hydroxycarbamide was weaned off as it failed to exhibit beneficial effect.

This case demonstrated that both Ruxolitinib and peg interferon used as single agents had no effect. When used in combination their effect was synergistic. Interestingly the previously poor tolerated peg-interferon side effects disappeared when combined with the Ruxolitinib.

Discussion

Based on British Society of Haematology guidelines Hydroxycarbamide remains a backbone of cytoreductive treatment [3]. Its role in leukemogenesis remains uncertain [4]. Other agents include previously mentioned INF and Anagrelide. Older drugs like Busulphan and radioactive phosphorous are rarely used because of the leukaemia risk especially in younger patients [10-11]. Interferon Alpha inhibits TPO dependant megakaryocytic growth [3]. Its use was originally limited by high rate of intolerable side effects such as fatigue, GI upset, affective disorders and lung and liver damage, which resulted in up to 20% drop out rate. Introduction of Pegylated preparations, which allowed once weekly administration improved tolerability with approx. 92% compliance and comparable long-term outcomes [3-6]. JAK inhibitors are primarily based on benzoimidazole core. Other agents with that structure display antihelminthic and antifungal properties. Ruxolitinib was the first drug in this class, originally approved by the FDA in 2011 and has been used in myelofibrosis for years as a single agent [7]. Recently guidance has approved its use in Polycythaemia Vera for those refractory to Hydroxycarbamide [8-9]. Sorensen et al. [2]. in their phase II single arm study explored use of Ruxolitinib in PV and pMF patients previously refractory or intolerant of INF-alpha2. Between 32-44% of patients have achieved complete or partial remission. Additionally combination treatment had improved response time, peripheral blood counts and marrow cellularity as well as decreased JAK2 allele burden [2,8]. Given similar cellular signalling pathway involved in aetiopathogenesis of both PV and ET, it is logical to assume that combination treatment could be efficacious in ET. However there is no published trial evidence to support its routine use. We would propose that given recognised molecular association between JAK-stat pathway and ET, as well other described cases of synergistic effect between PEG- Interferon and Ruxolitinib, a clinical trial to ascertain the combination efficacy would be warranted.

REFERENCES

1. AU Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. *Leukemia.* 2014; 28: 1472.
2. Sørensen AL, Mikkelsen SU, Knudsen TA. Ruxolitinib and interferon $\alpha 2$ combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. *Haematologica.* 2020; 105: 2262-2272.
3. Harrison CN, Bareford D, ButZ N, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. *British J Haematol.* 2010; 149: 352-375.
4. Finazzi G, Caruso V, Marchioli R. ECLAP Investigators. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. *Blood.* 2005; 105: 2664-2670.
5. Barosi G, Besses C, Birgegard G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. *Leukemia.* 2007; 21: 277-280.
6. Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: a review. *J Clin Oncol.* 1986; 4: 234-243.
7. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000SumR.pdf
8. Verstovsek S, Vannucchi AM, Griesshammer M, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. *Haematologica.* 2016; 101: 821-829.
9. McMullin MF, Harrison CN, Ali S, et al. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. *Br J Haematol.* 2019; 184: 176-191.
10. Van de Pette JE, Prochazka AV, Pearson TC, et al. Primary thrombocythaemia treated with busulphan. *British J Haematol.* 1986; 62: 229-237.
11. Randi ML, Fabris F, Varotto L, et al. Haematological complications in polycythaemia vera and thrombocythaemia patients treated with radiophosphorus (^{32}P). *Folia haematologica.* 1990; 117: 461-467.